Fig. 5
From: Enhanced bacterial cancer therapy delivering therapeutic RNA interference of c-Myc
Bacterial-mediated RNAi of c-Myc extends survival of BlgCre BRCA2flx/flxp53flx/flx mice. (A) SL7207/c-Myc(lux) expressing imaged as surface-grown culture (top panel) and dilutions of a submerged culture (bottom panel; cells/ml indicated. (B) In vivo luminescence imaging of tumour bearing BlgCre BRCA2flx/flxp53flx/flx mice 48 h after ip administration of 106 CFU of SL7207/c-Myc(lux). (C) Kaplan-meier survival curve indicating a significant increase in survival of mammary tumour mice delivered a single ip dose of 106 CFU of SL7207/c-Myc(lux)(green) versus control SL7207/SCR(lux) (blue; P = 0.014) and PBS (red; P = 0.023) mice (PBS vs. Scrambled P = 0.37; Mantel-Cox log rank test). (D) Luminescent imaging demonstrating persistence SL7207 bacteria in mammary tumours > 14 days following ip administration. (E) Western immunoblots (left panel) and densitometry quantification (right panel) of homogenised tumours indicating significant loss of c-Myc protein in SL7207/c-Myc(lux) colonised mammary tumours (P = 0.0175)